Reprogramming Aggressive Prostate Cancer to Enable Immune mediated Tumor Elimination
Reprogramming Aggressive Prostate Cancer to Enable Immune mediated Tumor Elimination - Paul Mathew - YouTube Breaking the Cold Tumor Barrier: New Bispecific Antibody Targets Hidden Enemy in Prostate Cancer BLUF (Bottom Line Up Front): Researchers at Tufts Medical Center have developed a novel bispecific antibody that could transform prostate cancer treatment by targeting aggressive "basal-type" cancer cells that evade the immune system, resist hormone therapy, and drive bone metastases. By simultaneously blocking two integrin proteins (alpha-5 and alpha-V), the antibody disrupts the mechanical signaling that allows cancer cells to hide from immune surveillance, potentially making prostate cancer responsive to immunotherapy for the first time. The treatment is being prepared for first-in-human clinical trials within the next year through spinout company Jolian Therapeutics. The Hidden Architecture of Aggressive Prostate Cancer For over two decades, Dr. Paul Mathew at Tufts...